These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 7863814)
1. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814 [TBL] [Abstract][Full Text] [Related]
2. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative. Russo D; Candoni A; Grattoni R; Minisini R; Rosti G Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589 [TBL] [Abstract][Full Text] [Related]
3. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042 [TBL] [Abstract][Full Text] [Related]
4. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959 [TBL] [Abstract][Full Text] [Related]
5. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Casato M; Laganà B; Antonelli G; Dianzani F; Bonomo L Blood; 1991 Dec; 78(12):3142-7. PubMed ID: 1742481 [TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3. Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083 [TBL] [Abstract][Full Text] [Related]
8. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Dammacco F; Sansonno D; Han JH; Shyamala V; Cornacchiulo V; Iacobelli AR; Lauletta G; Rizzi R Blood; 1994 Nov; 84(10):3336-43. PubMed ID: 7524736 [TBL] [Abstract][Full Text] [Related]
9. Deterioration of mixed cryoglobulinemia during treatment with interferon-alpha-2a. Bojić I; Lilić D; Radojcić C; Mijusković P J Gastroenterol; 1994 Jun; 29(3):369-71. PubMed ID: 8061808 [TBL] [Abstract][Full Text] [Related]
10. Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha. Tefferi A; Grendahl DC Am J Hematol; 1996 Jul; 52(3):231-3. PubMed ID: 8756097 [TBL] [Abstract][Full Text] [Related]
11. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. von Wussow P; Pralle H; Hochkeppel HK; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T Blood; 1991 Jul; 78(1):38-43. PubMed ID: 2070058 [TBL] [Abstract][Full Text] [Related]
12. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. Misiani R; Bellavita P; Fenili D; Vicari O; Marchesi D; Sironi PL; Zilio P; Vernocchi A; Massazza M; Vendramin G N Engl J Med; 1994 Mar; 330(11):751-6. PubMed ID: 8107741 [TBL] [Abstract][Full Text] [Related]
13. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes. Brand CM; Leadbeater L; Bellati G; Marotta F; Ideo G J Interferon Res; 1993 Apr; 13(2):121-5. PubMed ID: 7685368 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890 [TBL] [Abstract][Full Text] [Related]
16. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy. von Wussow P; Jakschies D; Freund M; Deicher H J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276 [TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Prümmer O Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526 [TBL] [Abstract][Full Text] [Related]
19. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163 [TBL] [Abstract][Full Text] [Related]
20. [The influence of interferon alpha neutralizing antibodies on the therapeutic effectiveness in patients with chronic viral hepatitis]. Tong F; Tang Y; Bai J Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Dec; 13(4):345-7. PubMed ID: 12759973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]